Clinical-stage USA-based drug developer Inhibikase Therapeutics saw its shares tumble more than 31% to $1.92, after is ...
Alterity Therapeutics ATHE shares moved upwards by 95.9% to $5.7 during Thursday's pre-market session. The market value of their outstanding shares is at $49.8 million. T ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback